drugset
Drugs / rAAV2-CB-hRPE65
last change Sep 2017 re-read 3 minutes ago

rAAV2-CB-hRPE65

Gene therapy (AAV / viral vector) targets RPE65

Developed for
Leber congenital amaurosis
Investigated by
Beacon Therapeutics · Oregon Health and Science University · University of Massachusetts, Worcester

Trials 1

today NCT00749957 · Ph 1/2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00749957 Jun 2009 → Sep 2014 Leber congenital amaurosis Beacon Therapeutics Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as rAAV2-CB-hRPE65 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00749957 ↗
Modality Gene therapy (AAV / viral vector) “a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65)” NCT00749957 ↗
Target RPE65 “a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65)” NCT00749957 ↗